Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 2, 2026, 9:15 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 75 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Budesonide / Formoterol Clear all
Completed Phase 3 Interventional Results available

New Breath Actuated MDI Symbicort Compared to Symbicort pMDI and Budesonide pMDI for 12 Weeks Twice a Day

NCT01360021
View directory record Official record
Conditions
Asthma
Interventions
Symbicort, Budesonide
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
12 Years and older
Enrollment
214 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
31
States / cities
Huntington Beach, California • Long Beach, California • Los Angeles, California + 28 more
Source: ClinicalTrials.gov public record
Updated Mar 11, 2014 · Synced Oct 2, 2026, 9:15 AM EDT
Completed Phase 4 Interventional Results available

A Randomized Study, Comparing Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Single Inhaler Triple Therapy, Versus Multiple Inhaler Therapy (Budesonide/Formoterol Plus Tiotropium) in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

NCT03478683
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
budesonide/formoterol, albuterol/salbutamol, FF/UMEC/VI, Placebo to match budesonide/formoterol, tiotropium, Placebo to match FF/UMEC/VI, placebo to match tiotropium, ELLIPTA, MDI, HandiHaler
Drug · Device
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
40 Years and older
Enrollment
729 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
40
States / cities
Gold River, California • Clearwater, Florida • DeBary, Florida + 31 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2020 · Synced Oct 2, 2026, 9:15 AM EDT
Completed No phase listed Observational

A Comparative Effectiveness Study of Mortality Outcomes and Related Cardiopulmonary Events Among a Cohort of Chronic Obstructive Pulmonary Disease (COPD) Patients Who Initiate Breztri and Multiple Inhaler Triple Therapy (MITT) in the United States (US)

NCT06744374
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
BGF, MITT
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
40 Years and older
Enrollment
22,369 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
1
States / cities
Wilmington, Delaware
Source: ClinicalTrials.gov public record
Updated Aug 27, 2025 · Synced Oct 2, 2026, 9:15 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Randomized, Crossover Safety and Pharmacokinetics Study of PT010

NCT02197975
View directory record Official record
Conditions
COPD
Interventions
PT010 Dose 1, PT010 Dose 2, Placebo MDI
Drug
Lead sponsor
Pearl Therapeutics, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 28, 2014 · Synced Oct 2, 2026, 9:15 AM EDT
Completed Not applicable Interventional Results available

Use of Symbicort or Pulmicort to Treat Viral-mediated Asthma Exacerbations

NCT01218399
View directory record Official record
Conditions
Asthma
Interventions
Symbicort
Drug
Lead sponsor
Stanford University
Other
Eligibility
12 Years to 65 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Aug 18, 2017 · Synced Oct 2, 2026, 9:15 AM EDT
Completed Phase 2 Interventional Results available

An Evaluation of Dupilumab in Patients With Moderate to Severe Uncontrolled Asthma

NCT01854047
View directory record Official record
Conditions
Asthma
Interventions
Dupilumab, placebo, ICS/LABA therapy, Salbutamol/albuterol, Levosalbutamol/levalbuterol
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
776 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
50
States / cities
Fullerton, California • Huntington Beach, California • Los Angeles, California + 38 more
Source: ClinicalTrials.gov public record
Updated Jun 26, 2017 · Synced Oct 2, 2026, 9:15 AM EDT
Completed Phase 3 Interventional

A Comparison of Symbicort® pMDI 2 x 160/4.5 μg Bid and Symbicort® pMDI 2 x 80/4.5 μg Bid With Formoterol Turbuhaler®, Budesonide pMDI, the Combination of Formoterol Turbuhaler® and Budesonide pMDI, and Placebo in COPD Patients

NCT00206154
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
Budesonide/formoterol pMDI, Budesonide pMDI, Formoterol Turbuhaler
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
40 Years and older
Enrollment
1,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
143
States / cities
Birmingham, Alabama • Jasper, Alabama • Mobile, Alabama + 140 more
Source: ClinicalTrials.gov public record
Updated Mar 27, 2009 · Synced Oct 2, 2026, 9:15 AM EDT
Completed Phase 3 Interventional Results available

Randomized, Placebo-controlled, Multi-dose, Study Comparing Budesonide/Formoterol to Symbicort® in Asthmatic Patients

NCT03015259
View directory record Official record
Conditions
Asthma
Interventions
Budesonide/Formoterol fumarate dihydrate, Symbicort, Placebo
Drug
Lead sponsor
Kindeva Drug Delivery
Industry
Eligibility
18 Years and older
Enrollment
1,762 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
95
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tempe, Arizona + 74 more
Source: ClinicalTrials.gov public record
Updated Aug 24, 2022 · Synced Oct 2, 2026, 9:15 AM EDT
Completed Phase 4 Interventional

Symbicort in Airway Predominant Chronic Obstructive Pulmonary Disease (COPD)

NCT01253473
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Budesonide, budesonide/formoterol, Ipratropium/albuterol
Drug
Lead sponsor
National Jewish Health
Other
Eligibility
45 Years to 80 Years
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
7
States / cities
Birmingham, Alabama • Torrance, California • Denver, Colorado + 4 more
Source: ClinicalTrials.gov public record
Updated Jan 19, 2021 · Synced Oct 2, 2026, 9:15 AM EDT
Completed No phase listed Observational

EXACERBATIONS AND REAL-WORLD OUTOMES INCLUDING CARDIOPULMONARY EVENTS AMONG PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (MITOS: EROS+CP US Study)

NCT06742736
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
BGF
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
40 Years and older
Enrollment
13,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
1
States / cities
Wilmington, Delaware
Source: ClinicalTrials.gov public record
Updated Aug 7, 2025 · Synced Oct 2, 2026, 9:15 AM EDT
Completed Phase 3 Interventional Results available

Study to Assess PT010 in Adult and Adolescent Participants With Inadequately Controlled Asthma (LOGOS)

NCT04609904
View directory record Official record
Conditions
Asthma
Interventions
BGF MDI 320/28.8/9.6 μg, BGF MDI 320/14.4/9.6 μg, BFF MDI 320/9.6 μg, BFF pMDI 320/9 μg
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
12 Years to 80 Years
Enrollment
2,187 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
88
States / cities
Chandler, Arizona • Tempe, Arizona • Tucson, Arizona + 78 more
Source: ClinicalTrials.gov public record
Updated Jul 2, 2026 · Synced Oct 2, 2026, 9:15 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetics and Safety Study of PT010 in Healthy Subjects

NCT02189304
View directory record Official record
Conditions
COPD
Interventions
PT010, PT009, Symbicort Turbohaler
Drug
Lead sponsor
Pearl Therapeutics, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
59 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 13, 2018 · Synced Oct 2, 2026, 9:15 AM EDT
Recruiting Phase 3 Interventional

A Study Evaluating the Efficacy of Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dosed Inhaler on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease

NCT06283966
View directory record Official record
Conditions
COPD (Chronic Obstructive Pulmonary Disease)
Interventions
BGF MDI 320/14.4/9.6 μg, GFF MDI 14.4/9.6 μg
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
40 Years to 80 Years
Enrollment
5,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
229
States / cities
Athens, Alabama • Cullman, Alabama • Fairhope, Alabama + 189 more
Source: ClinicalTrials.gov public record
Updated Aug 26, 2026 · Synced Oct 2, 2026, 9:15 AM EDT
Completed Phase 1Phase 2 Interventional

Symptom-driven ICS/LABA Therapy for Adolescent Patients With Asthma Non-adherent to Daily Maintenance Inhalers

NCT05689983
View directory record Official record
Conditions
Asthma in Children, Nonadherence, Medication
Interventions
Maintenance ICS and Symptom Driven SABA, Symptom-driven budesonide/formoterol combination
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
12 Years to 17 Years
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Aug 19, 2026 · Synced Oct 2, 2026, 9:15 AM EDT
Completed Phase 2 Interventional Results available

LIPS-B: Lung Injury Prevention Study With Budesonide and Beta

NCT01783821
View directory record Official record
Conditions
Acute Respiratory Distress Syndrome (ARDS)
Interventions
Budesonide, Placebo, Formoterol
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
5
States / cities
Tucson, Arizona • Stanford, California • Jacksonville, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 5, 2016 · Synced Oct 2, 2026, 9:15 AM EDT
Completed Phase 3 Interventional Results available

Randomized, Placebo-Controlled, Multidose, Study Comparing Generic Budesonide/Formoterol Fumarate Dihydrate to Symbicort® in Asthmatic Participants

NCT02495168
View directory record Official record
Conditions
Asthma
Interventions
Generic Budesonide/Formoterol Fumarate Dihydrate, Symbicort® (Budesonide/Formoterol Fumarate Dihydrate), Placebo
Drug
Lead sponsor
Actavis Inc.
Industry
Eligibility
12 Years to 75 Years
Enrollment
1,714 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
17
States / cities
Surprise, Arizona • Huntington Beach, California • San Jose, California + 12 more
Source: ClinicalTrials.gov public record
Updated Nov 29, 2019 · Synced Oct 2, 2026, 9:15 AM EDT
Active, not recruiting Phase 3 Interventional

Open-label Study to Assess Reduction of Background Asthma Medication While Sustaining Asthma Control and Clinical Remission With Tezepelumab in Patients 12-80yrs With Severe Asthma.

NCT06473779
View directory record Official record
Conditions
Severe Asthma
Interventions
Tezepelumab, Budesonide/formoterol, Albuterol/budesonide (AIRSUPRA®), Mannitol, Salbutamol
Combination Product
Lead sponsor
AstraZeneca
Industry
Eligibility
12 Years to 80 Years
Enrollment
326 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
8
States / cities
Palmdale, California • Colorado Springs, Colorado • Miami, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Jun 15, 2026 · Synced Oct 2, 2026, 9:15 AM EDT
Completed Phase 4 Interventional Results available

A Randomized Study, Comparing Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC /VI) Single Inhaler Triple Therapy, Versus Multiple Inhaler Therapy (Budesonide/Formoterol Plus Tiotropium) in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

NCT03478696
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
budesonide/formoterol, albuterol/salbutamol, FF/UMEC/VI, Placebo to match budesonide/formoterol, tiotropium, Placebo to match FF/UMEC/VI, placebo to match tiotropium, ELLIPTA, MDI, HandiHaler
Drug · Device
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
40 Years and older
Enrollment
732 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
42
States / cities
Mobile, Alabama • Bakersfield, California • Sacramento, California + 35 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2020 · Synced Oct 2, 2026, 9:15 AM EDT
Completed Phase 3 Interventional Results available

A Comparison of SYMBICORT® pMDI With Budesonide HFA pMDI in African American Subjects With Asthma.

NCT00419952
View directory record Official record
Conditions
Asthma
Interventions
Budesonide/formoterol (SYMBICORT) pMDI, Budesonide HFA pMDI
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
12 Years and older
Enrollment
742 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
122
States / cities
Birmingham, Alabama • Mobile, Alabama • Montgomery, Alabama + 119 more
Source: ClinicalTrials.gov public record
Updated Oct 30, 2012 · Synced Oct 2, 2026, 9:15 AM EDT
Completed Phase 2 Interventional Results available

A Study in Asthmatic Children (6 to <12 Yrs) Comparing Single Doses of Formoterol and Foradil® Evaluating Efficacy

NCT01136655
View directory record Official record
Conditions
Asthma
Interventions
80/2.25 μg Symbicort pMDI, 80/4.5 μg Symbicort pMDI, Foradil Aerolizer 12 μg, 40 μg budesonide HFA pMDI, placebo HFA pMDI
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
6 Years to 11 Years
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
20
States / cities
Huntington, California • Long Beach, California • Mission Viejo, California + 17 more
Source: ClinicalTrials.gov public record
Updated Oct 31, 2013 · Synced Oct 2, 2026, 9:15 AM EDT
Terminated Not applicable Interventional Results available

The Effects of Different Long-acting Bronchodilator Medications on Asthma Patients With Different Genetic Variations

NCT00706446
View directory record Official record
Conditions
Asthma
Interventions
tiotropium bromide, Salmeterol, Formoterol, Fluticasone propionate, budesonide
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 75 Years
Enrollment
255 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 31, 2017 · Synced Oct 2, 2026, 9:15 AM EDT
Active, not recruiting Phase 2 Interventional

Study of Lunsekimig (SAR443765) Compared With Placebo in Adults With High-risk Asthma

NCT06676319
View directory record Official record
Conditions
Asthma
Interventions
Lunsekimig, Short-Acting Beta Agonists (SABA), Placebo, Fluticasone/Salmeterol, Budesonide/Formoterol, Budesonide/Albuterol
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 80 Years
Enrollment
556 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
53
States / cities
Saraland, Alabama • Chandler, Arizona • Sun City, Arizona + 47 more
Source: ClinicalTrials.gov public record
Updated Sep 22, 2026 · Synced Oct 2, 2026, 9:15 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Symptom-driven ICS/LABA Therapy for Patients With Asthma Non-adherent to Daily Maintenance Inhalers

NCT05111262
View directory record Official record
Conditions
Asthma, Nonadherence, Medication
Interventions
Adherence to symptom driven budesonide/formoterol as compared to adherence to maintenance ICS and symptom-driven SABA
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
12 Years to 75 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Aug 19, 2026 · Synced Oct 2, 2026, 9:15 AM EDT
Completed Phase 3 Interventional Results available

Study to Assess the Safety and Tolerability of PT010, PT009 and PT003 in Subjects With Moderate to Very Severe Chronic Obstructive Pulmonary Disease

NCT02536508
View directory record Official record
Conditions
COPD
Interventions
BGF MDI 320/14.4/9.6 μg, GFF MDI 14.4/9.6 μg, BFF MDI 320/9.6 μg
Drug
Lead sponsor
Pearl Therapeutics, Inc.
Industry
Eligibility
40 Years to 80 Years
Enrollment
627 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
64
States / cities
Dothan, Alabama • Jasper, Alabama • Peoria, Arizona + 56 more
Source: ClinicalTrials.gov public record
Updated Feb 26, 2021 · Synced Oct 2, 2026, 9:15 AM EDT